Zydus Lifesciences’ NCE (novel Chemical Entity) Usnoflast has received ‘Fast Track Designation’ from the United States Food and Drug Administration (USFDA). Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).
A drug that receives Fast Track Designation from the USFDA is eligible for accelerated approval and priority review, if the relevant criteria are met. The purpose of Fast Track Designation is to get important new drugs to the patients faster.
Zydus Lifesciences is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
